General use cases
- Carcinoma, Ovarian Epithelial
- Fallopian Tube Neoplasms
- Peritoneal Neoplasms
- adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
